First in Human Dose Escalation Study of Vactosertib (TEW-7197) in Subjects With Advanced Stage Solid Tumors
Completed
National OncoVenture
Phase 1
The phase I dose escalation study will investigate the safety, tolerability, and
pharmacokinetics of the TGF-β pathway inhibitor TEW 7197 in subjects with advanced,
refractory solid tumors.
First in Human Dose Escalation Study of Vactosertib (TEW-7197) in Subjects With Advanced Stage Solid Tumors
Completed
MedPacto, Inc.
Phase 1
The phase I dose escalation study will investigate the safety, tolerability, and
pharmacokinetics of the TGF-β pathway inhibitor TEW 7197 in subjects with advanced,
refractory solid tumors.
Dose Escalation and Proof-of-Concept Studies of Vactosertib (TEW-7197) Monotherapy in Patients With MDS
Completed
MedPacto, Inc.
Phase 1
This is a prospective, open-label, multicenter, phase 1/2 study of TEW-7197 in patients with
low and intermediate risk of myelodysplastic syndrome (MDS).
Vactosertib in Combination w/ Pomalidomide in Relapsed or Relapsed and Refractory Multiple Myeloma
Recruiting
Case Comprehensive Cancer Center
Phase 1
The purpose of this study is to see if the study drug, called Vactosertib, is safe and
determine what the best dose is to treat future patients when given in combination with
pomalidomide (POM). The study will also look to see if it has any effect on multiple myeloma,
when given in combination with POM.
TEW-7197 With Paclitaxel for the Treatment of Metastatic Gastric Cancer
Active, not recruiting
MedPacto, Inc.
Phase 1/Phase 2
This is an open-label, single arm study evaluating the safety and tolerability of TEW-7197 in
combination with paclitaxel in metastatic gastric cancer patients.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
